Topic
1 story, newest first.
Merck and Moderna announced positive phase three trial results for a personalised mRNA cancer vaccine combined with Keytruda, reducing melanoma recurrence and spread in high-risk patients. The treatment met its primary goal, with stock prices rising on the news. Further data will determine regulatory approval timelines.
